Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1990 1
1991 4
1992 2
1993 3
1994 3
1995 4
1996 4
1997 8
1998 4
1999 3
2000 4
2001 2
2002 4
2003 6
2004 6
2005 4
2006 8
2007 7
2008 11
2009 7
2010 9
2011 7
2012 8
2013 9
2014 10
2015 11
2016 12
2017 8
2018 19
2019 9
2020 9
2021 28
2022 12
2023 19
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

251 results

Results by year

Filters applied: . Clear all
Page 1
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.
Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, Völkl S, Simon D, Kleyer A, Munoz L, Kretschmann S, Kharboutli S, Gary R, Reimann H, Rösler W, Uderhardt S, Bang H, Herrmann M, Ekici AB, Buettner C, Habenicht KM, Winkler TH, Krönke G, Schett G. Mackensen A, et al. Nat Med. 2022 Oct;28(10):2124-2132. doi: 10.1038/s41591-022-02017-5. Epub 2022 Sep 15. Nat Med. 2022. PMID: 36109639
CAR T-cell therapy in autoimmune diseases.
Schett G, Mackensen A, Mougiakakos D. Schett G, et al. Among authors: mackensen a. Lancet. 2023 Nov 25;402(10416):2034-2044. doi: 10.1016/S0140-6736(23)01126-1. Epub 2023 Sep 22. Lancet. 2023. PMID: 37748491 Review.
CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.
Müller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, Völkl S, Aigner M, Rothe T, Minopoulou I, Tur C, Knitza J, Kharboutli S, Kretschmann S, Vasova I, Spoerl S, Reimann H, Munoz L, Gerlach RG, Schäfer S, Grieshaber-Bouyer R, Korganow AS, Farge-Bancel D, Mougiakakos D, Bozec A, Winkler T, Krönke G, Mackensen A, Schett G. Müller F, et al. Among authors: mackensen a. N Engl J Med. 2024 Feb 22;390(8):687-700. doi: 10.1056/NEJMoa2308917. N Engl J Med. 2024. PMID: 38381673
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus.
Mougiakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboutli S, Böltz S, Manger B, Mackensen A, Schett G. Mougiakakos D, et al. Among authors: mackensen a. N Engl J Med. 2021 Aug 5;385(6):567-569. doi: 10.1056/NEJMc2107725. N Engl J Med. 2021. PMID: 34347960 No abstract available.
CD19-targeted CAR T cells in refractory antisynthetase syndrome.
Müller F, Boeltz S, Knitza J, Aigner M, Völkl S, Kharboutli S, Reimann H, Taubmann J, Kretschmann S, Rösler W, Manger B, Wacker J, Mougiakakos D, Jabari S, Schröder R, Uder M, Roemer F, Krönke G, Mackensen A, Schett G. Müller F, et al. Among authors: mackensen a. Lancet. 2023 Mar 11;401(10379):815-818. doi: 10.1016/S0140-6736(23)00023-5. Epub 2023 Feb 15. Lancet. 2023. PMID: 36930673 No abstract available.
Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells.
Bergmann C, Müller F, Distler JHW, Györfi AH, Völkl S, Aigner M, Kretschmann S, Reimann H, Harrer T, Bayerl N, Boeltz S, Wirsching A, Taubmann J, Rösler W, Spriewald B, Wacker J, Atzinger A, Uder M, Kuwert T, Mackensen A, Schett G. Bergmann C, et al. Among authors: mackensen a. Ann Rheum Dis. 2023 Aug;82(8):1117-1120. doi: 10.1136/ard-2023-223952. Epub 2023 May 5. Ann Rheum Dis. 2023. PMID: 37147112 Free PMC article. No abstract available.
LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells.
Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A, Matos C, Bruss C, Klobuch S, Peter K, Kastenberger M, Bogdan C, Schleicher U, Mackensen A, Ullrich E, Fichtner-Feigl S, Kesselring R, Mack M, Ritter U, Schmid M, Blank C, Dettmer K, Oefner PJ, Hoffmann P, Walenta S, Geissler EK, Pouyssegur J, Villunger A, Steven A, Seliger B, Schreml S, Haferkamp S, Kohl E, Karrer S, Berneburg M, Herr W, Mueller-Klieser W, Renner K, Kreutz M. Brand A, et al. Among authors: mackensen a. Cell Metab. 2016 Nov 8;24(5):657-671. doi: 10.1016/j.cmet.2016.08.011. Epub 2016 Sep 15. Cell Metab. 2016. PMID: 27641098 Free article.
Author Correction: Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.
Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, Völkl S, Simon D, Kleyer A, Munoz L, Kretschmann S, Kharboutli S, Gary R, Reimann H, Rösler W, Uderhardt S, Bang H, Herrmann M, Ekici AB, Buettner C, Habenicht KM, Winkler TH, Krönke G, Schett G. Mackensen A, et al. Nat Med. 2023 Nov;29(11):2956. doi: 10.1038/s41591-022-02091-9. Nat Med. 2023. PMID: 36329355 No abstract available.
Inhibitory effect of tumor cell-derived lactic acid on human T cells.
Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, Gottfried E, Schwarz S, Rothe G, Hoves S, Renner K, Timischl B, Mackensen A, Kunz-Schughart L, Andreesen R, Krause SW, Kreutz M. Fischer K, et al. Among authors: mackensen a. Blood. 2007 May 1;109(9):3812-9. doi: 10.1182/blood-2006-07-035972. Epub 2007 Jan 25. Blood. 2007. PMID: 17255361 Free article. Clinical Trial.
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.
Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, Mougiakakos D, Frölich L, Ackermann J, Bücklein V, Blumenberg V, Schmidt C, Jallades L, Fehse B, Faul C, Karschnia P, Weigert O, Dreyling M, Locke FL, von Bergwelt-Baildon M, Mackensen A, Bethge W, Ayuk F, Bachy E, Salles G, Jain MD, Subklewe M. Rejeski K, et al. Among authors: mackensen a. Blood. 2021 Dec 16;138(24):2499-2513. doi: 10.1182/blood.2020010543. Blood. 2021. PMID: 34166502 Free PMC article.
251 results